Table of Contents Author Guidelines Submit a Manuscript
Journal of Biomedicine and Biotechnology
Volume 2009, Article ID 973754, 8 pages
http://dx.doi.org/10.1155/2009/973754
Research Article

Generation and Characterization of Novel Human IRAS Monoclonal Antibodies

1Department of Pharmacology, Beijing Institute of Pharmacology and Toxicology, Beijing 100850, China
2Department of Pathophysiology, Beijing Institute of Radiation Medicine, Beijing 100850, China

Received 10 February 2009; Revised 18 May 2009; Accepted 5 June 2009

Academic Editor: Val J. Watts

Copyright © 2009 Bo Wang et al. This is an open access article distributed under the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited.

Linked References

  1. P. Bousquet, J. Feldman, and J. Schwartz, “Central cardiovascular effects of alpha adrenergic drugs: differences between catecholamines and imidazolines,” Journal of Pharmacology and Experimental Therapeutics, vol. 230, no. 1, pp. 232–236, 1984. View at Google Scholar
  2. P. Ernsberger, M. E. Graves, L. M. Graff et al., “I1-imidazoline receptors: definition, characterization, distribution, and transmembrane signaling,” Annals of the New York Academy of Sciences, vol. 763, pp. 22–42, 1995. View at Publisher · View at Google Scholar
  3. F. Tesson and A. Parini, “Identification of an imidazoline-guanidinium receptive site in mitochondria from rabbit cerebral cortex,” European Journal of Pharmacology, vol. 208, no. 1, pp. 81–83, 1991. View at Publisher · View at Google Scholar
  4. S. L. F. Chan, C. A. Brown, K. E. Scarpello, and N. G. Morgan, “The imidazoline site involved in control of insulin secretion: characteristics that distinguish it from I1- and I2-sites,” British Journal of Pharmacology, vol. 112, no. 4, pp. 1065–1070, 1994. View at Google Scholar
  5. G. J. Molderings, “Imidazoline receptors: basic knowledge, recent advances and future prospects for therapy and diagnosis,” Drugs of the Future, vol. 22, no. 7, pp. 757–772, 1997. View at Google Scholar
  6. P. Ernsberger, T. H. Damon, L. M. Graff, S. G. Schäfer, and M. O. Christen, “Moxonidine, a centrally acting antihypertensive agent, is a selective ligand for I1-imidazoline sites,” Journal of Pharmacology and Experimental Therapeutics, vol. 264, no. 1, pp. 172–182, 1993. View at Google Scholar
  7. F. Tesson, I. Limon-Boulez, P. Urban et al., “Localization of I2-imidazoline binding sites on monoamine oxidases,” Journal of Biological Chemistry, vol. 270, no. 17, pp. 9856–9861, 1995. View at Publisher · View at Google Scholar
  8. R. Raddatz, A. Parini, and S. M. Lanier, “Localization of the imidazoline binding domain on monoamine oxidase B,” Molecular Pharmacology, vol. 52, no. 4, pp. 549–553, 1997. View at Google Scholar
  9. N. G. Morgan, S. L. F. Chan, C. A. Brown, and E. Tsoli, “Characterization of the imidazoline binding site involved in regulation of insulin secretion,” Annals of the New York Academy of Sciences, vol. 763, pp. 361–373, 1995. View at Publisher · View at Google Scholar
  10. R. Raddatz, A. Parini, and S. M. Lanier, “Imidazoline/guanidinium binding domains on monoamine oxidases: relationship to subtypes of imidazoline-binding proteins and tissue-specific interaction of imidazoline ligands with monoamine oxidase B,” Journal of Biological Chemistry, vol. 270, no. 46, pp. 27961–27968, 1995. View at Publisher · View at Google Scholar
  11. J. E. Piletz, A. C. Andorn, J. R. Unnerstall, and A. Halaris, “Binding of [3H]-p-aminoclonidine to α2-adrenoceptor states plus a non-adrenergic site on human platelet plasma membranes,” Biochemical Pharmacology, vol. 42, no. 3, pp. 569–584, 1991. View at Publisher · View at Google Scholar
  12. P. Ernsberger and I.-H. Shen, “Membrane localization and guanine nucleotide sensitivity of medullary I1-imidazoline binding sites,” Neurochemistry International, vol. 30, no. 1, pp. 17–23, 1997. View at Publisher · View at Google Scholar
  13. F. M. J. Heemskerk, M. Dontenwill, H. Greney, C. Vonthron, and P. Bousquet, “Evidence for the existence of imidazoline-specific binding sites in synaptosomal plasma membranes of the bovine brainstem,” Journal of Neurochemistry, vol. 71, no. 5, pp. 2193–2202, 1998. View at Google Scholar
  14. J. E. Piletz, T. R. Ivanov, J. D. Sharp et al., “Imidazoline receptor antisera-selected (IRAS) cDNA: cloning and characterization,” DNA and Cell Biology, vol. 19, no. 6, pp. 319–329, 2000. View at Publisher · View at Google Scholar
  15. M. Dontenwill, G. Pascal, J. E. Piletz et al., “IRAS, the human homologue of Nischarin, prolongs survival of transfected PC12 cells,” Cell Death and Differentiation, vol. 10, no. 8, pp. 933–935, 2003. View at Publisher · View at Google Scholar
  16. M. Dontenwill, J. E. Piletz, M. Chen et al., “IRAS is an anti-apoptotic protein,” Annals of the New York Academy of Sciences, vol. 1009, pp. 400–412, 2003. View at Publisher · View at Google Scholar
  17. L. Dupuy, D. Urosevic, H. Greney et al., “I1 imidazoline receptor-mediated effects on apoptotic processes in PC12 cells,” Cell Death and Differentiation, vol. 11, no. 9, pp. 1049–1052, 2004. View at Publisher · View at Google Scholar
  18. J. E. Piletz, G. Wang, and H. Zhu, “Cell signaling by imidazoline-1 receptor candidate, IRAS, and the nischarin homologue,” Annals of the New York Academy of Sciences, vol. 1009, pp. 392–399, 2003. View at Publisher · View at Google Scholar
  19. S. K. Alahari, J. W. Lee, and R. L. Juliano, “Nischarin, a novel protein that interacts with the integrin α5 subunit and inhibits cell migration,” Journal of Cell Biology, vol. 151, no. 6, pp. 1141–1154, 2000. View at Publisher · View at Google Scholar
  20. Z. Sun, C. H. Chang, and P. Ernsberger, “Identification of IRAS/Nischarin as an I1-imidazoline receptor in PC12 rat pheochromocytoma cells,” Journal of Neurochemistry, vol. 101, pp. 99–108, 2007. View at Google Scholar
  21. G. J. Molderings, H. Bőnisch, M. Brűss, C. Wolf, I. von Kűgelgen, and M. Gőthert, “S1P-receptors in PC12 and transfected HEK293 cells: molecular targets of hypotensive imidazoline I1 receptor ligands,” Neurochemistry International, vol. 51, no. 8, pp. 476–485, 2007. View at Publisher · View at Google Scholar
  22. N. Wu, R.-B. Su, B. Xu et al., “IRAS, a candidate for I1-imidazoline receptor, mediates inhibitory effect of agmatine on cellular morphine dependence,” Biochemical Pharmacology, vol. 70, no. 7, pp. 1079–1087, 2005. View at Publisher · View at Google Scholar
  23. H. Zhu, J. Hayes, M. Chen, J. Baldwin, and J. E. Piletz, “Relationship between platelet imidazoline receptor-binding peptides and candidate imidazoline-1 receptor, IRAS,” Annals of the New York Academy of Sciences, vol. 1009, pp. 439–446, 2003. View at Publisher · View at Google Scholar
  24. C. P. Ponting, “Novel domains in NADPH oxidase subunits, sorting nexins, and PtdIns 3- kinases: binding partners of SH3 domains?” Protein Science, vol. 5, no. 11, pp. 2353–2357, 1996. View at Google Scholar
  25. P. N. Nelson, G. M. Reynolds, E. E. Waldron, E. Ward, K. Giannopoulos, and P. G. Murray, “Monoclonal antibodies,” Molecular Pathology, vol. 53, no. 3, pp. 111–117, 2000. View at Google Scholar
  26. X. Yuan, Y. Cong, J. Hao et al., “Regulation of LIP level and ROS formation through interaction of H-ferritin with G-CSF receptor,” Journal of Molecular Biology, vol. 339, no. 1, pp. 131–144, 2004. View at Publisher · View at Google Scholar
  27. X. Yuan, J. Li, Y. Shan et al., “Subcellular localization and membrane association of SARS-CoV 3a protein,” Virus Research, vol. 109, no. 2, pp. 191–202, 2005. View at Publisher · View at Google Scholar
  28. L.-W. Deng, I. Chiu, and J. L. Strominger, “MLL5 protein forms intranuclear foci, and overexpression inhibits cell cycle progression,” Proceedings of the National Academy of Sciences of the United States of America, vol. 101, no. 3, pp. 757–762, 2004. View at Publisher · View at Google Scholar
  29. R. G. Harrison, “Expression of soluble heterologous proteins via fusion with NusA protein,” Innovations, vol. 11, pp. 4–7, 2000. View at Google Scholar
  30. K.-P. Lim and W. Hong, “Human nischarin/imidazoline receptor antisera-selected protein is targeted to the endosomes by a combined action of a PX domain and a coiled-coil region,” Journal of Biological Chemistry, vol. 279, no. 52, pp. 54770–54782, 2004. View at Publisher · View at Google Scholar
  31. B. Zheng, Y. C. Ma, R. S. Ostrom et al., “RGS-PX1, a GAP for GalphaS and sorting nexin in vesicular trafficking,” Science, vol. 294, pp. 1845–1847, 2001. View at Google Scholar